Inivata has moved one step closer to the full commercialization of its RaDaR assay, which can detect 48 subvariants of tumor DNA, with the publication of clinical validation data from its LIONESS study.
The trial took blood samples from 17 patients with stage III-IVB, p16-negative head and neck squamous cell carcinoma who had...